32133-37-2 Usage
General Description
DL-3,5-difluorophenylalanine is a synthetic amino acid analog that contains two fluorine atoms attached to the phenyl ring of the phenylalanine molecule. It is commonly used in the field of chemical biology and medicinal chemistry to study protein-ligand interactions and to design novel drugs. Its incorporation into proteins can alter their function and stability, making it a valuable tool for studying the structure-function relationships of proteins. Additionally, it has been investigated for its potential therapeutic applications, particularly in the development of new cancer treatments. DL-3,5-difluorophenylalanine has shown promise as a potential anticancer agent, as well as in the development of novel antibiotics.
Check Digit Verification of cas no
The CAS Registry Mumber 32133-37-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,1,3 and 3 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 32133-37:
(7*3)+(6*2)+(5*1)+(4*3)+(3*3)+(2*3)+(1*7)=72
72 % 10 = 2
So 32133-37-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H9F2NO2/c10-6-1-5(2-7(11)3-6)8(12)4-9(13)14/h1-3,8H,4,12H2,(H,13,14)
32133-37-2Relevant articles and documents
Optimization and mechanistic studies of psammaplin A type antibacterial agents active against methicillin-resistant Staphylococcus aureus (MRSA)
Nicolaou,Hughes,Hughes, Robert,Pfefferkorn,Pfefferkorn, Jeffrey A.,Barluenga,Barluenga, Sofia
, p. 4296 - 4310 (2007/10/03)
As described in the preceding article, utilizing a novel combinatorial disulfide exchange strategy, a library of psammaplin A (1) analogues was constructed and screened for antibacterial activity leading to the identification of a collection of diverse lead compounds. These combinatorial leads were subsequently refined, through parallel synthesis, to afford a series of highly potent antibacterial agents (e.g. 17, 57, 58, 69, and 70), some possessing greater than 50-fold higher activities than the natural product. Evaluation of the selectivity and serum binding properties of some of the most promising compounds and preliminary studies directed at deciphering the mechanism of action of this novel class of antibacterial agents are also included.